Kroger to Offer Eli Lilly's Popular Zepbound KwikPen, Expanding Access to Savings
KR sits 27% above its 52-week low of $58.6.
Summary
Kroger announced it will now stock Eli Lilly's highly sought-after Zepbound KwikPen for weight loss and will allow self-pay customers to utilize Lilly's savings card at its pharmacies. This strategic move positions Kroger to capitalize on the significant and growing demand for GLP-1 therapies, potentially driving increased pharmacy sales and customer foot traffic across its network. For Eli Lilly, this expands the distribution and accessibility of its key product. This development is a positive operational catalyst for Kroger, enhancing its competitive offering in the retail pharmacy space.
At the time of this announcement, KR was trading at $74.39 on NYSE in the Trade & Services sector, with a market capitalization of approximately $47.1B. The 52-week trading range was $58.60 to $76.58. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.